Effect of two medicines, Vijaysaradi Ghanvati and Madhumehari Vati in the treatment of Madhumeha (Type 2 Diabetes )

Clinical Study on Vijaysaradi Ghanvati and Madhumehari Vati in the Management of Madhumeha (Type 2 Diabetes ) - An Open Randomized Comparative Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/05/008618

Enrollment

Registered

2017-05-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Madhumeha (Type 2 Diabetes) Health Condition 2: E119- Type 2 diabetes mellitus without complications Health Condition 3: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Madhumehari Vati: Madhumehari Vati will be given in Madhumeha patients in dose of 1 tablet (800mg) tds with plain water before food for 8 weeks. Control Intervention1: Vijaysaradi Ghan

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having signs and symptoms of Madhumeha (Type 2 Diabetes) 2. Fasting plasma glucose >= 126 mg/dl or Post Prandial glucose level >= 200 mg/dl.

Exclusion criteria

Exclusion criteria: 1. Age less than 20 years more than 70 years. 2. Patients of Diabetes mellitus receiving Insulin. 3. Patients having chronic complications of Diabetes mellitus like Retinopathy, Neuropathy Nephropathy, Coronary artery disease, Peripheral vascular disease, Cerebro-vascular disease and other chronic debilitating disease like STD etc. 4. pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
efficacyTimepoint: 2 month	—

Secondary

Measure	Time frame
safetyTimepoint: 2 month	—

Countries

India

Contacts

Public ContactSachin Kumar Sharma

IPGT and RA Gujarat ayurved university

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026